Dabigatran etexilate 220 mg
|
Major VTE and VTE-related mortality
|
4.0% (23/578)
|
2.7% (29/1080)
|
2.7% (10/369)
|
OR (95% CI) versus general anaesthesia
| |
0.67 (0.37–1.22)
|
0.67 (0.28–1.49)
|
MBE
|
0.9% (7/785)
|
1.7% (24/1379)
|
1.4% (7/497)
|
OR (95% CI) versus general anaesthesia
| |
1.97 (0.82–5.43)
|
1.59 (0.47–5.34)
|
MBE/CRBE
|
4.8% (38/785)
|
5.9% (81/1379)
|
6.0% (30/497)
|
OR (95% CI) versus general anaesthesia
| |
1.23 (0.82–1.87)
|
1.26 (0.74–2.12)
|
Dabigatran etexilate 150 mg
|
Major VTE and VTE-related mortality
|
5.1% (30/587)
|
3.2% (35/1082)
|
3.3% (13/395)
|
OR (95% CI) versus general anaesthesia
| |
0.62 (0.37–1.06)
|
0.63 (0.30–1.27)
|
MBE
|
1.3% (10/781)
|
1.0% (14/1403)
|
0.8% (4/530)
|
OR (95% CI) versus general anaesthesia
| |
0.78 (0.32–1.97)
|
0.59 (0.13–2.05)
|
MBE/CRBE
|
5.4% (42/781)
|
5.4% (76/1403)
|
6.6% (35/530)
|
OR (95% CI) versus general anaesthesia
| |
1.01 (0.67–1.52)
|
1.24 (0.76–2.03)
|
Enoxaparin
|
Major VTE and VTE-related mortality
|
3.5% (20/566)
|
3.2% (37/1143)
|
3.1% (12/383)
|
OR (95% CI) versus general anaesthesia
| |
0.91 (0.51–1.68)
|
0.88 (0.39–1.92)
|
MBE
|
1.3% (10/745)
|
1.5% (21/1430)
|
1.6% (8/512)
|
OR (95% CI) versus general anaesthesia
| |
1.10 (0.49–2.62)
|
1.17 (0.40–3.31)
|
MBE/CRBE
|
4.6% (34/745)
|
5.6% (80/1430)
|
4.5% (23/512)
|
OR (95% CI) versus general anaesthesia
| |
1.24 (0.81–1.93)
|
0.98 (0.55–1.74)
|